|

Androgen Deprivation Therapy Clinical Trials

8 actively recruiting trials across 4 locations

Also known as: ADT

Pipeline

Phase 2: 3Phase 3: 4

Top Sponsors

  • UNICANCER2
  • Zin W Myint1
  • University of Virginia1
  • University of Miami1
  • Universitaire Ziekenhuizen KU Leuven1

Indications

  • Cancer8
  • Prostate Cancer6
  • Hormone Sensitive Prostate Cancer2
  • Prostate Cancer Metastatic2
  • Prostate Adenocarcinoma2

Other4 trials

ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
Phase 3
Implementation of Precision Medicine in High-risk Prostate Cancer
Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
Phase 3
Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging
Phase 3

Miami, Florida1 trial

PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer

University of Miami

Phase 2

Kansas City, Kansas1 trial

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

University of Kansas Medical Center

Phase 3

Lexington, Kentucky1 trial

Pembro With Radiation With or Without Olaparib

University of Kentucky

Phase 2

Charlottesville, Virginia1 trial

EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer

University of Virginia

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.